CAR T cell therapy in solid tumors: A review of current clinical trials

eJHaem

article

Urvi Patel PharmD¹  John Abernathy MS²  Bipin N Savani MD³  Olalekan Oluwole MD³  Salyka Sengsayadeth MD³  Bhagirathbhai Dholaria MD³ 

[1] College of Pharmacy, The University of Tennessee Health Science Center;College of Medicine, The University of Tennessee Health Science Center;Department of Hematology- Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

关键词: CAR T cell therapy;    clinical trials;    solid tumors;   

DOI  :  10.1002/jha2.356

来源: Wiley

【 摘 要 】

Chimeric antigen receptor (CAR) T cell therapy has made tremendous strides in the arena of hematological malignancies with approved therapies in certain leukemias, lymphomas, and recently myeloma with overall highly favorable response rates. While numerous clinical studies are still ongoing for hematological malignancies, research is developing to translate the feasibility of CAR T therapy in solid organ malignancies. Unfortunately, the majority of diagnosed cancers are primarily solid tumors. Thus, a highly unmet clinical need for further research and development exists in this field. This review article highlights currently active clinical trials and a few pertinent preclinical studies involving CAR T cell therapy in solid tumors while briefly discussing study outcomes and potential key targets that may allow for the feasibility of this therapy option. Finally, we mention critical challenges existing in the solid tumor environment and discuss developing strategies that may potentially overcome the existing barriers to CAR T cell progress in solid tumors.

【 授权许可】

Unknown